5 Best Mid-Cap Healthcare Stocks To Buy Now

In this article, we discuss 5 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 11 Best Mid-Cap Healthcare Stocks To Buy Now. 

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 39

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company that focuses on the development of curative therapeutics for transthyretin amyloidosis, hereditary angioedema, deficiency-liver disease, deficiency-lung disease, lymphomas, hemophilia A and hemophilia B, acute myeloid leukemia, and various cancers and autoimmune diseases. It is one of the best healthcare stocks to invest in. 

On April 13, Whitney Ijem, an analyst at Canaccord, gave Intellia Therapeutics, Inc. (NASDAQ:NTLA) a Buy rating with a price target of $66. According to the analyst, the company’s focus on in-vivo gene editing in large, rare indications may not be the quickest route to the clinic compared to other CRISPR-based companies, but Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s methodical approach has yielded positive results. The Phase 1 data from Intellia’s lead program, NTLA-2001, in ATTR, and wholly-owned NTLA-2002 in HAE, is said to look promising in terms of both safety and efficacy. The company’s progress through Phase 2 and into pivotal studies over the next 6-12 months is expected to provide additional opportunities for value creation, the analyst told investors. 

According to Insider Monkey’s fourth quarter database, 39 hedge funds were bullish on Intellia Therapeutics, Inc. (NASDAQ:NTLA), compared to 36 funds in the prior quarter. Cathie Wood’s ARK Investment Management is the largest stakeholder of the company, with 9.4 million shares worth $328.7 million. 

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”